Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03874754 Not yet recruiting - Hypertension Clinical Trials

Tailored Home-Based Exercise Program for Multiple Chronic Conditions

iHBE
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

A home-based, tailored, technology-enhanced home-based exercise program (iHBE) using a combination of the integrated mobile technologies (wearable device and phone application) and tailored home-based exercise will be pilot tested. Participants will choose one of the four home-based exercise options [National Institute of Aging (NIA) Go4Life (an exercise and physical activity campaign from the NIA), Iyengar-style yoga, walking, and modified Otago exercise] based on participants' preference and goals. The integrated mobile technologies system will allow the investigators to extract heart rate data directly from the wearable device to the research server. This data will be used to provide appropriate and personalized feedback on physical performance. The survey and notification to the participants on the smartphone.

NCT ID: NCT03874065 Not yet recruiting - Cancer Clinical Trials

Medical Data Collection in the Formation of Procision Oncology Registry

Start date: May 2019
Phase:
Study type: Observational [Patient Registry]

In efforts to develop an aggregation point for patient clinical data and data related to DNA sequencing in the Comprehensive Cancer Center, this registry will be developed to provide a comprehensive data store. The goal of the registry will be to collect information on the Cancer Center population undergoing next generation DNA sequencing (NGS) on their tumors or liquid biopsies.

NCT ID: NCT03873493 Not yet recruiting - Cancer Clinical Trials

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-cell Prolymphocytic Leukemia

Start date: June 6, 2019
Phase: Phase 2
Study type: Interventional

A study to evaluate the safety and efficacy of venetoclax plus ibrutinib for participants with T-cell Prolymphocytic Leukemia (T-PLL) and follows a 2-stage design as follows: Stage 1: Enroll up to 14 participants and move to Stage 2 if 4 or more subjects meet protocol-specified response criteria. Response assessment will be performed on a continued basis until all 14 participants have enrolled into Stage 1 and have completed the Week 24 disease assessment. Stage 2: Enroll up to an additional 23 participants with previously untreated or relapsed or refractory T-PLL.

NCT ID: NCT03868046 Not yet recruiting - Cancer Clinical Trials

Autoantibodies in Treatment With Immune Checkpoint Inhibitors (AUTENTIC)

AUTENTIC
Start date: March 15, 2019
Phase:
Study type: Observational

The aim of this study is to assess the effectiveness of a battery of autoantibodies to predict the occurrence of immune-related adverse events (irAEs) in patients with cancer who will be treated with immune checkpoint inhibitors (ICIs) per standard protocol.

NCT ID: NCT03857776 Not yet recruiting - Cancer Clinical Trials

Open Dialogue About Complementary Alternative Medicine (CAM) Integrated in Conventional Oncology Care

Start date: March 2019
Phase: N/A
Study type: Interventional

The purpose of this phase two parallel-group randomized controlled trial is to assess the efficacy of open dialogue about CAM integrated in conventional oncology care. The investigators hypothesize that patients in the intervention group participating in a scheduled open dialogue with a nurse specialist about CAM will experience better physical and mental health compared to patients in the control group receiving standard care alone.

NCT ID: NCT03856463 Not yet recruiting - Cancer Clinical Trials

Coaches Activating Reaching and Engaging Patients

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

The purpose of the Team Based Advance Care Planning CAREPLAN program is to understand if a trained lay navigator who engages with patients with advanced stages of cancer can help patients in advance care planning, improve patient activation, satisfaction, quality of life, and the quality of end of life cancer care while also ensuring goal concordant cancer care at the end of life.

NCT ID: NCT03847649 Not yet recruiting - Cancer Clinical Trials

Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity

Start date: March 31, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects being re-treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with durvalumab, can reduce any side effects.

NCT ID: NCT03844048 Not yet recruiting - Cancer Clinical Trials

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Start date: March 4, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.

NCT ID: NCT03843957 Not yet recruiting - Cancer Clinical Trials

Effectiveness and Implementation of mPATH-CRC

Start date: June 2019
Phase: N/A
Study type: Interventional

Study Investigators are conducting this study to learn how to best implement a new iPad program in clinical practice.

NCT ID: NCT03842917 Not yet recruiting - Cancer Clinical Trials

SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF)

SAVE
Start date: March 2019
Phase:
Study type: Observational

Bevacizumab is an anti-angiogenic treatment used to treat various solid cancers. Previous studies have shown that this treatment may have adverse effects like hypertension and proteinuria. This is an exploratory study aiming to better understand the relationship between various biomarkers and blood pressure changes and proteinuria measured for 4 to 6 weeks after the first infusion of anti-VEGF therapy with bevacizumab.